# Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer

> **NCT06656598** · PHASE2 · RECRUITING · sponsor: **Intergroupe Francophone de Cancerologie Thoracique** · enrollment: 152 (estimated)

## Conditions studied

- Stage III NSCLC

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Cemiplimab
- **RADIATION:** Curative hypofractionated radiotherapy
- **DRUG:** Cemiplimab (maintenance)

## Key facts

- **NCT ID:** NCT06656598
- **Lead sponsor:** Intergroupe Francophone de Cancerologie Thoracique
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-07
- **Primary completion:** 2028-09
- **Final completion:** 2032-01
- **Target enrollment:** 152 (ESTIMATED)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06656598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06656598, "Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06656598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*